Singapore’s Everstone Capital Invests $270 Million in India’s…

Sarah J · 2026-04-17T16:20:36.000Z

Singapore-based private equity firm Everstone Capital has invested close to $270 million for a substantial stake in India’s Apothecon Group, marking a major transaction in the pharmaceutical manufacturing and specialty formulations sector. The deal reflects growing investor confidence in India’s life sciences ecosystem and its role in global healthcare supply chains. The investment has been made in partnership with the founding promoters of India-based Apothecon and US-based Navinta, creating a combined platform focused on regulated markets and specialty formulations. The group operates with integrated capabilities across formulations manufacturing, captive API production, and commercial operations spanning the United States, Europe, and other international markets. Founded in 2003 by industry veterans Dr. Mahendra Patel and Joe Renner, Apothecon has built a diversified portfolio across injectables, oral solids, and other complex dosage forms. The company maintains manufacturing and R&D operations in Vadodara and Hyderabad in India, along with facilities in New Jersey and Florida in the United States. Everstone Capital plans to use the investment to accelerate the company’s product pipeline, expand commercial reach into new geographies, and pursue strategic acquisitions. Existing promoters will continue to retain a meaningful stake, ensuring continuity of leadership and operational expertise. European partner Waymade also participated in the transaction through its investment arm, underscoring the cross-border nature of the deal. The transaction highlights a broader trend of private equity capital flowing into India’s pharmaceutical sector, particularly businesses with export-oriented models, regulatory capabilities, and differentiated product portfolios. As global healthcare companies seek resilient supply chains and alternative manufacturing hubs, Indian pharma platforms are increasingly attracting strategic and financial investors. For India, this investment further strengthens its reputation as a global center for pharmaceutical innovation, manufacturing, and specialty generics. With growing demand across regulated markets such as the US and Europe, deals like this are expected to drive the next phase of expansion in the country’s healthcare industry.

Member Login Get Access

Singapore’s Everstone Capital Invests $270 Million in India’s… | SEINET